Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 4/2016

Open Access 01-04-2016 | Research Paper

MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively

Authors: Youguang Pu, Fangfang Zhao, Wenjing Cai, Xianghui Meng, Yinpeng Li, Shanbao Cai

Published in: Clinical & Experimental Metastasis | Issue 4/2016

Login to get access

Abstract

MicroRNAs have been identified as key players in the development and progression of osteosarcoma, which is the most common primary malignancy of bone. Sequencing-based miR-omic and quantitative real-time PCR analyses suggested that the expression of miR-193a-3p and miR-193a-5p was decreased by DNA methylation at their promoter region in a highly metastatic osteosarcoma cell line (MG63.2) relative to their expression in the less metastatic MG63 cell line. Further wound-healing and invasion assays demonstrated that both miR-193a-3p and miR-193a-5p suppressed osteosarcoma cell migration and invasion. Moreover, introducing miR-193a-3p and miR-193a-5p mimics into MG63.2 cells or antagomiRs into MG63 cells confirmed their critical roles in osteosarcoma metastasis. Additionally, bioinformatics prediction along with biochemical assay results clearly suggested that the secretory small GTPase Rab27B and serine racemase (SRR) were direct targets of miR-193a-3p and miR-193a-5p, respectively. These two targets are indeed involved in the miR-193a-3p- and miR-193a-5p-induced suppression of osteosarcoma cell migration and invasion. MiR-193a-3p and miR-193a-5p play important roles in osteosarcoma metastasis through down-regulation of the Rab27B and SRR genes and therefore may serve as useful biomarkers for the diagnosis of osteosarcoma and as potential candidates for the treatment of metastatic osteosarcoma.
Literature
1.
2.
Yang J, Zhang W (2013) New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol 25(4):398–406CrossRefPubMed
3.
Kaste SC et al (1999) Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer 86(8):1602–1608CrossRefPubMed
4.
Letson GD, Muro-Cacho CA (2001) Genetic and molecular abnormalities in tumors of the bone and soft tissues. Cancer Control 8(3):239–251PubMed
5.
6.
Ragland BD et al (2002) Cytogenetics and molecular biology of osteosarcoma. Lab Investig 82(4):365–373CrossRefPubMed
7.
Su Y et al (2009) Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clin Exp Metastasis 26(7):599–610CrossRefPubMed
8.
Su Y et al (2011) Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene 30(37):3907–3917CrossRefPubMed
9.
10.
Ameres SL, Zamore PD (2013) Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 14(8):475–488CrossRefPubMed
11.
12.
13.
14.
15.
Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15–20CrossRefPubMed
16.
17.
Goldberger N et al (2013) Inherited variation in miR-290 expression suppresses breast cancer progression by targeting the metastasis susceptibility gene Arid4b. Cancer Res 73(8):2671–2681CrossRefPubMedPubMedCentral
18.
Yang H et al (2013) MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology 58(1):205–217CrossRefPubMed
19.
Zheng B et al (2011) MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 17(24):7574–7583CrossRefPubMed
20.
Chen L et al (2013) miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS Lett 587(9):1366–1372CrossRefPubMed
21.
Cao ZQ, Shen Z, Huang WY (2013) MicroRNA-802 promotes osteosarcoma cell proliferation by targeting p27. Asian Pac J Cancer Prev 14(12):7081–7084CrossRefPubMed
22.
Luo XJ et al (2014) MicroRNA-212 inhibits osteosarcoma cells proliferation and invasion by down-regulation of Sox4. Cell Physiol Biochem 34:2180–2188CrossRefPubMed
23.
24.
Heller G et al (2012) Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res 18(6):1619–1629CrossRefPubMed
25.
Avci CB et al (2013) Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev 14(2):765–768CrossRefPubMed
26.
Deng H et al (2014) miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway. Mol Cancer 13:234CrossRefPubMedPubMedCentral
27.
Yang Y et al (2013) A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma. Oncogene 32(29):3432–3442CrossRefPubMed
28.
Yu T et al (2015) MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene 34(4):413–423CrossRefPubMed
29.
Shiraishi M, Hayatsu H (2004) High-speed conversion of cytosine to uracil in bisulfite genomic sequencing analysis of DNA methylation. DNA Res 11(6):409–415CrossRefPubMed
30.
Hayatsu H, Negishi K, Shiraishi M (2004) Accelerated bisulfite-deamination of cytosine in the genomic sequencing procedure for DNA methylation analysis. Nucleic Acids Symp Ser (Oxf) 48:261–262CrossRef
31.
Tahiri A et al (2014) Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 35(1):76–85CrossRefPubMed
32.
33.
Yong FL, Law CW, Wang CW (2013) Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer 13:280CrossRefPubMedPubMedCentral
34.
Montojo J et al (2014) GeneMANIA: fast gene network construction and function prediction for Cytoscape. F1000Research 3:153
35.
Wang J et al (2013) Demethylation of miR-9-3 and miR-193a genes suppresses proliferation and promotes apoptosis in non-small cell lung cancer cell lines. Cell Physiol Biochem 32(6):1707–1719CrossRefPubMed
36.
Gao XN et al (2011) MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 30(31):3416–3428CrossRefPubMed
37.
38.
Ma K et al (2012) DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem 287(8):5639–5649CrossRefPubMedPubMedCentral
39.
Lv L et al (2014) The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell Death Dis 5:e1402CrossRefPubMedPubMedCentral
40.
Bonnette MD et al (2009) dcDegenerate oligonucleotide primed-PCR for multilocus, genome-wide analysis from limited quantities of DNA. Diagn Mol Pathol 18(3):165–175CrossRefPubMed
41.
Lin Q et al (2009) RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J Cancer Res Clin Oncol 135(12):1675–1684CrossRefPubMed
42.
Fukuda M (2008) Regulation of secretory vesicle traffic by Rab small GTPases. Cell Mol Life Sci 65(18):2801–2813CrossRefPubMed
43.
Pereira-Leal JB, Seabra MC (2001) Evolution of the Rab family of small GTP-binding proteins. J Mol Biol 313(4):889–901CrossRefPubMed
44.
Zerial M, McBride H (2001) Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2(2):107–117CrossRefPubMed
45.
Pfeffer SR (2005) Structural clues to Rab GTPase functional diversity. J Biol Chem 280(16):15485–15488CrossRefPubMed
46.
Bao J et al (2014) Rab27b is a potential predictor for metastasis and prognosis in colorectal cancer. Gastroenterol Res Pract 2014:913106PubMedPubMedCentral
47.
Dong WW et al (2012) Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma. World J Gastroenterol 18(15):1806–1813CrossRefPubMedPubMedCentral
48.
Zhang JX et al (2012) Overexpression of the secretory small GTPase Rab27B in human breast cancer correlates closely with lymph node metastasis and predicts poor prognosis. J Transl Med 10:242CrossRefPubMedPubMedCentral
49.
Hendrix A et al (2010) Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst 102(12):866–880CrossRefPubMedPubMedCentral
50.
Hendrix A et al (2013) Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer. Int J Cancer 133(4):843–854CrossRefPubMed
51.
Ostenfeld MS et al (2014) Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res 74(20):5758–5771CrossRefPubMed
52.
Xiao L et al (2013) NMDA receptor couples Rac1-GEF Tiam1 to direct oligodendrocyte precursor cell migration. Glia 61(12):2078–2099CrossRefPubMed
53.
Choi SW et al (2004) The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinoma. J Oral Pathol Med 33(9):533–537CrossRefPubMed
54.
Zhang P et al (2014) Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer. World J Gastroenterol 20(34):12241–12248CrossRefPubMedPubMedCentral
55.
Zhang Q, Yu N, Lee C (2014) Vicious cycle of TGF-beta signaling in tumor progression and metastasis. Am J Clin Exp Urol 2(2):149–155PubMedPubMedCentral
56.
57.
Zhu H et al (2014) Activating transcription factor 4 promotes esophageal squamous cell carcinoma invasion and metastasis in mice and is associated with poor prognosis in human patients. PLoS One 9(7):e103882CrossRefPubMedPubMedCentral
58.
Wu ZY et al (2014) Activating transcription factor 3 promotes colon cancer metastasis. Tumour Biol 35(8):8329–8334CrossRefPubMed
59.
Cao H, Yang ZX, Jiang GQ (2013) Expression and clinical significance of activating transcription factor 3 in human breast cancer. Iran J Basic Med Sci 16(11):1151–1154PubMedPubMedCentral
60.
Yuan X et al (2013) ATF3 suppresses metastasis of bladder cancer by regulating gelsolin-mediated remodeling of the actin cytoskeleton. Cancer Res 73(12):3625–3637CrossRefPubMed
61.
Jan YH et al (2012) Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3. Cancer Res 72(19):5119–5129CrossRefPubMed
Metadata
Title
MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively
Authors
Youguang Pu
Fangfang Zhao
Wenjing Cai
Xianghui Meng
Yinpeng Li
Shanbao Cai
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 4/2016
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-016-9783-0

Other articles of this Issue 4/2016

Clinical & Experimental Metastasis 4/2016 Go to the issue

Research Paper

Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Research Paper

β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases

Research Paper

Metformin may protect nondiabetic breast cancer women from metastasis

Research Paper

Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer

Research Paper

Repositioning “old” drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion

Research Paper

Characterization of passive permeability at the blood–tumor barrier in five preclinical models of brain metastases of breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits